Open AccessInhibition of Aberrant Activated Fibroblast‐Like Synoviocytes in Rheumatoid Arthritis by Leishmania Peptide via the Regulation of Fatty Acid Synthesis Metabolism
Author(s) -
Su Jianling,
Fan Xuemei,
Zou Yaoyao,
Fu Guangtao,
Feng Shiqi,
Wang Xiaoxue,
Yu Yongmei,
Li Lin,
Bian Zhenhua,
Huang Rongrong,
Qin Linmang,
Chen Jiping,
Zeng Qin,
Yan Kai,
Gao Caiyue,
Lian Zhexiong,
Li Xin,
Li Yang
Publication year - 2025
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.202409154
Subject(s) - fatty acid synthase , adipocyte protein 2 , microbiology and biotechnology , fatty acid metabolism , chemistry , pi3k/akt/mtor pathway , fatty acid , signal transduction , biology , biochemistry
Abstract The Leishmania homolog of receptors for activated C kinase (LACK) protein is derived from Leishmania parasites L. major . The polypeptide LACK 156–173 has been shown to confer protection against murine autoimmune arthritis. Fibroblast‐like synoviocytes (FLSs) play a pivotal role in the synovial invasion and joint destruction observed in rheumatoid arthritis (RA). The study reveals that LACK 156‐173 can inhibit the aggressive phenotype of RA‐FLSs by restoring dysregulated fatty acid synthesis metabolism. In RA‐FLSs, overexpression of fatty acid synthase (FASN) leads to excessive fatty acid accumulation, which in turn promotes mitochondrial fragmentation by enhancing phosphorylation at the ser616 site of dynamin 1‐like protein (DRP1). This process increases reactive oxygen species (ROS) production and activates the PI3K/mTOR/NF‐κB pathway, thereby facilitating the transition of RA‐FLSs to an aggressive inflammatory and bone‐damaging phenotype. LACK 156‐173 is internalized into the cytoplasm via CAPN2‐mediated endocytosis, where it directly binds to FASN and inhibits its activity. The findings suggest that targeting the restoration of fatty acid metabolism could potentially alleviate synovial invasion and joint damage in RA. LACK 156‐173 may therefore hold therapeutic promise for RA patients.